Bibliography
- Woodcock J . Chutes and ladders on the critical path: comparative effectiveness, product value, and the use of biomarkers in drug development. Clin. Pharmacol. Ther. 86(1), 12–14 (2009).
- Colburn WA . Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol. 43(4), 329–341 (2003).
- Bowsher RR , SailstadJM. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug metabolism: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand. J. Pharm. Biomed. Anal. 48, 1282–1289 (2008).
- Lee JW , DevanarayanV, BarrettYCet al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23, 312–328 (2006).
- Bowsher RR , SailstadJM. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug metabolism: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand. J. Pharm. Biomed. Anal. 48, 1282–1289 (2008).
- Lee JW , SmithWC, NordblomGD, BowsherRR. Validation of assays for the bioanalysis of novel biomarkers. In:Biomarkers in Clinical Drug Development. Bloom JC, Dean RA (Eds). Marcel Dekker, NY, USA 119–149 (2003).
- Nowatzke W , ColeTG, BowsherRR. Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development. Bioanalysis2(2), 237–247 (2010).
- Shah VP , MidhaKK, DigheSet al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Pharm. Res. 9, 588–592 (1992).
- US FDA. Guidance for Industry on Bioanalytical Method Validation. Federal Register66, 28526–28527 (2001).
- Viswanathan CT , BansalS, BoothBet al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand-binding assays. Pharm. Res. 24(10), 1962–1973 (2007).